Evidence map›Paper›PMID 34516351›Full record

ArticleBioengineered2021

Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.

Cheng Wang, Miaomiao Yang, Xi Gu, Yanjing Gu

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Cheng WangEndoscopy and Laparoscopy Center, Changzhou No.3 People's Hospital, Changzhou, Jiangsu, China.
Miaomiao YangEndoscopy and Laparoscopy Center, Changzhou No.3 People's Hospital, Changzhou, Jiangsu, China.ORCID 0000-0001-5188-0683
Xi GuEndoscopy and Laparoscopy Center, Changzhou No.3 People's Hospital, Changzhou, Jiangsu, China.
Yanjing GuEndoscopy and Laparoscopy Center, Changzhou No.3 People's Hospital, Changzhou, Jiangsu, China.
World Laparoscopy Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As an oncogenic kinase in multiple cancers, LMTK3 was deeply implicated in cancer pathogenesis. Nevertheless, its biological function in colorectal cancer (CRC) is still unclear. In this study, LMTK3 mRNA expression was assessed by RT-qPCR. LMTK3, phospho-ERK1/2 (p-ERK1/2), ERK1/2, and cleaved caspase-3 protein levels were detected by western blotting. Cetuximab (CTX)-resistant CRC cell models were constructed to investigate the mechanism of LMTK3-regulated CTX resistance in CRC. CTX half-maximal inhibitory concentration (IC

Indexed as

Colorectal NeoplasmsDrug Resistance, NeoplasmMAP Kinase Signaling SystemMembrane ProteinsProtein Serine-Threonine KinasesAdultAntineoplastic Agents, ImmunologicalApoptosisCell Line, TumorCetuximabFemaleGene Knockdown TechniquesHumansMaleAntineoplastic Agents, ImmunologicalCetuximabLMTK3 protein, humanMembrane ProteinsProtein Serine-Threonine Kinasescetuximabcolorectal cancerERK/MAPKLMTK3resistance

Identifiers

PMID34516351
PMCPMC8806509
OpenAlexW3199316202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.